To determine the effects of steel factor (SIF) on the number and distribution of phenotypically defined hematopoietic stem cells in vivo, mice were treated with continuous s.c. infusions of SIF for up to 7 days. The bone marrow demonstrated a transient 5-fold increase in the number of c-kit-positive lineage-negative/low cells with no change in cellularity. The Hematopoietic stem cells (HSCs) maintain the continuous production of all cell lineages in the hematolymphoid system throughout the life time ofhigher vertebrates. To produce the requisite number of highly specialized cells in response to a variety of physiologic stimuli, these cells must be capable of differentiation into committed progenitor cells while retaining the capacity for self-renewal. Presently, the mechanisms that govern these processes are poorly understood. We have previously described a method for the isolation of phenotypically defined HSCs from murine bone marrow (BM) (1, 2). Subsequent studies have demonstrated that this population of cells, which exhibits low levels of Thy-1 expression, high levels of Sca-1 expression, and the absence or low levels of blood cell lineage marker expression (hereafter referred to as Sca+ cells), contains all the HSC activity found in normal BM (3). By using this highly enriched HSC population, it is now possible to study those factors that may regulate either the proliferation or the developmental programs of these primitive cells.
ABSTRACT
To determine the effects of steel factor (SIF) on the number and distribution of phenotypically defined hematopoietic stem cells in vivo, mice were treated with continuous s.c. infusions of SIF for up to 7 days. The bone marrow demonstrated a transient 5-fold increase in the number of c-kit-positive lineage-negative/low cells with no change in cellularity. The radioprotective capacity of bone marrow cells was significantiy reduced, and a 30% decrease in Thy1" Lin/0 Sca-1+ stem cells (Sca+ cells) was observed. In marked contrast, in the spleen a 2-fold increase in cellularity was accompanied by a 24-fold increase in c-kit-positive lineagenegative/low cells. SIF-treated spleen cells provided increased radioprotection and a corresponding 4-fold increase in the number of Sca+ cells. In the peripheral blood, an increase in both neutrophils and lymphocytes resulted; however, the number ofc-kit-positive lineage-negative/low cells remained <1% . SIF produced a 25-fold increase in radioprotection capacity and a 20-fold increase in the number of Sca+ cells in the peripheral blood. The increased radioprotection capacity of both the spleen cells and peripheral blood cells was associated with donor-derived, long-term multilineage reconstitution of recipient mice. The total number of Sca+ cells isolated per mouse after SIF treatment was not significantiy increased.
These results show that exogenous SIF treatment causes a redistribution of Sca+ cells and stem cell activity while having little effect on the total number of stem cells in the mouse.
Hematopoietic stem cells (HSCs) maintain the continuous production of all cell lineages in the hematolymphoid system throughout the life time ofhigher vertebrates. To produce the requisite number of highly specialized cells in response to a variety of physiologic stimuli, these cells must be capable of differentiation into committed progenitor cells while retaining the capacity for self-renewal. Presently, the mechanisms that govern these processes are poorly understood. We have previously described a method for the isolation of phenotypically defined HSCs from murine bone marrow (BM) (1, 2) . Subsequent studies have demonstrated that this population of cells, which exhibits low levels of Thy-1 expression, high levels of Sca-1 expression, and the absence or low levels of blood cell lineage marker expression (hereafter referred to as Sca+ cells), contains all the HSC activity found in normal BM (3) . By using this highly enriched HSC population, it is now possible to study those factors that may regulate either the proliferation or the developmental programs of these primitive cells.
Steel factor (SIF), the c-kit ligand also called stem cell factor and mast cell growth factor, has been implicated in a wide variety of physiologic processes including melanocyte migration, primordial germ-cell development, mast cell function, and hematopoiesis (4) (5) (6) (7) (8) (9) . A number of recent studies have demonstrated the superadditive effect of SIF both in vitro and in vivo when administered in combination with other hematopoietic growth factors, such as granulocyte/ macrophage colony-stimulating factor, granulocyte colonystimulating factor, interleukin 3, and erythropoietin (10) (11) (12) (13) (14) (15) . In addition, antibodies that block the binding of SIF to its receptor have been shown to deplete the number of hematopoietic progenitors in murine BM dramatically (16) . Treatment of enriched HSC populations in vitro with SIF and interleukin 3 leads to proliferation of these cells and an increase in both colony-forming cells and colony-forming unit-spleen activity (17, 18 tTo whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" Radioprotection Assay. Recipient mice were lethally irradiated by using a Phillips 250-kV x-ray machine at 100 rads (1 rad = 0.01 Gy)/min in two fractions at least 3 hr apart to a total of 9 Gy (or for C57BL/Ka-Ly5.1 to 8. (Fig. 1) . In the BM, a transient 5-fold increase in c-kit+/Lin-/l0 cell number was seen after 3 days of SIF treatment, which then returned to baseline by day 7 (Fig. 1A) . In contrast, in the spleen c-kit+/Lin/Ao cells represented <1% of total spleen cells in vehicle-treated controls but demonstrated a sustained increase reaching 12% of total spleen cells after 7 days of SlF treatment (Fig. 1B) . This increase in Lin/lO cells was accompanied by a 2-fold increase in spleen cellularity resulting in a net 24-fold increase in these cells (Table 1) .
After 7 days of SIF treatment, a 4-fold increase in total PB leukocytes was observed. This leukocytosis was primarily due to a 24-fold increase in neutrophils that was accompanied by a 1.7-fold increase in circulating lymphoid cells (Table 1) . These changes in the PB are similar to those reported recently by Molineux et al. (19) .
SI Enhances the Radioprotective Capacity ofPB and Spleen.
To test the effect of SIF on cells that confer protection against lethal irradiation, various doses of unfractionated cells from the BM, spleen, and PB of SlF-treated mice were tested for their ability to rescue irradiated mice. Fig. 2 shows that 2 x 104 vehicle-treated BM cells protected 43% of recipient mice, whereas only 3% of mice survived after receiving the same number of cells from SlF-treated donors. In contrast, 4 x 104 spleen cells from vehicle-treated controls failed to provide detectable radioprotection, whereas 2 x 104 SlF-treated donor spleen cells rescued 22% ofrecipients, and 4 x 104 SiF-treated donor spleen cells rescued 58% of recipients (Fig. 3) . Increased radioprotective capacity of PB cells from SIF-treated donors was also observed. Although 250 A of unfractionated PB from vehicle-treated donors was required to rescue 21% of recipients, only 10 A4 of PB from SlF-treated mice provided radioprotection to 30%6 of recipients (Fig. 4) .
Radioprotecdon Is Associated with Donor-Derived Reconstitution. To determine whether the increased radioprotection observed with SIF treatment in both spleen and PB cells was due to transient engraftment of donor cells that permitted the subsequent recovery of radio-resistant host stem cells, or due to sustained donor-derived multilineage hematopoiesis, we used donor and recipient mice that were congenic at the LyS locus (1). The results of this multilineage long-term reconstitution assay in representative individual mice is shown in Fig.  5 . Most nucleated cells in the PB of animals rescued with 4 x 104 SlF-treated donor spleen cells were of donor origin 10 mo after lethal irradiation. Specifically, 99%o ofB cells (anti-B220), 89o of myelomonocytic cells (anti-MAC-1 and anti-GR-1), and 73% ofT cells (anti-CD3) were donor-derived (Fig. SA) . In mice rescued with 30 ,ul of PB cells from SlF-treated donors, the majority of circulating nucleated cells were found to be of donor origin, as were 96% of B cells, 97% of myelomonocytic cells, and 94% of T cells (Fig. SB) .
SW Increases the Number of Phenotypicafly Defined HSCs in the PB and Spleen. To determine whether the increased radioprotection and multilineage reconstitution capacity of PB and spleen cells from SlF-treated mice could result from an increase in phenotypically defined HSC populations, we isolated Sca+ stem cells from the BM, spleen, and PB ofmice treated with SIF. In the BM we observed a decrease in the number of Sca+ cells from 27,000 to 19,000 after 7 days of SIF treatment (Table 2 ). In contrast, the number of Scal cells in the spleen increased nearly 4-fold with SIF treatment.
As a variety of hematopoietic growth factors are believed to mobilize early hematopoietic progenitor cells into the PB, we examined the effect of SIF on the number of Scal cells in this compartment. The PB demonstrated an increase in Sca+ cell number from 250 to 5000 per mouse. Although SlF treatment increased the number of Scal cells in both the spleen and PB, these changes were offset by a decrease in BM-derived Sca+ cells. The total number of Sca+ cells isolated per mouse did not significantly increase (Table 2 ).
DISCUSSION
The c-kit receptor is expressed on a variety of enriched HSC populations (16) (17) (18) including Scal cells (20) . SI/SI mice homozygous for a deletion of the SIF gene die in utero in the setting of profound anemia, suggesting that this growth factor may have an important role in regulating the developmental potential of HSCs. However, the fetal liver of Sl/Sl mice contains Sca+ HSCs at =40% of the level found in +/+ or +/S1 littermates, indicating that SlF may not be necessary for the initial generation and early expansion of HSCs (19) . SlF treatment of Sca+ cells in vitro had little effect other than as a survival factor, but SIF in combination with interleukin 3 or interleukin 6 led to a massive proliferation of cells involving -40%-50% of input Sca+ cells, resulting in large numbers of myeloerythroid progeny (J. Friedman, S. Heimfeld, and I.L.W., unpublished work). It was therefore ofinterest to test whether SlF treatment in vivo could engage Sca+ cells in such activation pathways, and if so, how it would influence both the size and distribution of the stem cell pool. Here we demonstrate that the treatment of mice with exogenous SIF causes a marked redistribution of HSCs while having little effect on total stem cell number.
In the BM, both the radioprotection capacity and Sca+ cell number decrease after 7 days of SlF treatment. BM cells from vehicle-treated mice provided radioprotection to 42% of recipients, a result similar to that observed for BM from untreated donors. In contrast, BM from SlF-treated mice protected only 3% ofrecipients. A concomitant 30% decrease in Sca+ cells was seen in the SlF-treated mice. The loss of radioprotective capacity of the BM associated with SlF treatment is greater than would be anticipated from a 30% decrease in the number of Sca+ cells that should result in only a 15-20% decrease in radioprotection (1) . Although the reasons for this difference remain unclear, possible mechanisms include a defect in the ability of Sca+ cells from SlF-treated animals to "home" to the BM of irradiated recipient mice, or possibly SlF treatment may produce changes in the developmental potential of these cells. Alternatively, a subpopulation of HSCs that primarily provides radioprotection may be inhibited by exogenous SlF.
In the mouse, the spleen remains a site of active hematopoiesis during adult life, contributing continually to the formed elements in the PB (21) . Histologic evaluation indicates that after SlF treatment both erythropoiesis and megakaryopoiesis are increased (data not shown), a finding reported in other species (14) . SlF treatment also results in the accumulation of a significant number of c-kit+/Lin-/lo cells in the spleen accompanied by a 2-fold increase in spleen cell number. The appearance of spleen cells expressing c-kit is accompanied by a dramatic increase in the radioprotection capacity of spleen cells on a per cell basis. As few as 4 x 104 spleen cells from SlF-treated animals will rescue 58% of irradiated recipients, whereas 4 x 104 spleen cells from vehicle-treated donors fail to provide any degree of radioprotection. A corresponding 4-fold increase in the number of Sca+ cells is seen after SlF treatment. Sustained donorderived, long-term multilineage reconstitution confirms the presence of stem cell activity in this population.
The presence of functional HSCs in the PB of mice, as defined by the capacity for radioprotection and long-term myeloid and erythroid reconstitution, was first reported >30 yr ago (22) . A number of studies have since demonstrated that the colony-forming unit-spleen activity of PB in mice is increased in the setting of severe anemia (23) , in response to bacterial endotoxin (24) , and after treatment with SlF (19) . The administration of granulocyte-colony-stimulating factor results in a dramatic increase in the radioprotection capacity of PB (25) . Our results show that only 10 Al of PB from SlF-treated mice will rescue 30% of irradiated recipients, whereas 250 ,l of PB from control mice is required to provide a similar degree of radioprotection. The results of these radioprotection studies correlate well with the 20-fold increase in the number of Sca+ cells seen in the PB of SlF-treated mice. The true stem cell activity of these PB cells is confirmed by their ability to provide long-term, donorderived multilineage reconstitution. These findings are consistent with those of Andrews et al. (26) , who have demonstrated that SlF treatment increases the number of CD34+ cells in the PB of baboons. This group has also recently demonstrated that PB mononuclear cells from SlF-treated donors have an increased capacity for both early engraftment and for the protection of lethally irradiated recipients (27) .
These studies, however, did not examine whether these SlF-mobilized PB cells have the capacity to provide longterm donor-derived hematopoiesis.
SIF treatment of mice reduces both the HSC activity and the number of Sca+ cells in the BM, which offsets increases in the number and activity of these cells in the PB and spleen. Consequently, no significant increase in the total number of Sca+ cells isolated per mouse was observed. These results indicate that the treatment of mice with exogenous SIF does not lead to significant expansion of Sca+ cells. These studies provide further evidence that factors other than SIF are likely to be required for both the expansion and self-renewal of HSCs in vivo.
